Who is looking to control a million shares of ino and is so sure of positive prospects by aug that they are willing to have a breakeven of 3.35??
Shorts post endlessly, but bullish money talks....................follow it......
Lieberman Quote: "We just aren't going to do any acquisition. Shareholders should be happy we haven't used the cash for a bad acquisition." The hubris and stupidity of that statement goes right to the heart of their attitude for shareholders.
The balls of these guys when you think that not one of them has bought a share with his own money in the open market. If we want a buyback, it should be done. The fact is that their last acquisition did nothing to enhance shareholder value. When I pointed this out to Lieberman, his response was silence.
They want to keep cash for one reason; to pay their bloated salaries and bonuses.
According to Castle, compensation for Ma used this peer group analysis. And based on Castle's extensive work(he was paid over 100k to be on the compensation committee) Ma was underpaid. Of course, I could easily find another peer group which would say just the opposite. Its a joke, but not very funny to shareholders. By the way, Castle is also underpaid; according to him anyway. A bigger blowhard would be difficult to find.
An interesting comment from Castle was that he used public and private companys in his analysis. But, last I checked, private company CEO's DO NOT make their pay package public.
Whats next for group? Write company a demand a list of all shareholders. As per sec, they must provide.
A peer group is a list of comparator companies selected by compensation committees, institutional investors and proxy advisors to serve as a market benchmark for evaluating executive pay levels and comparing pay design. Benchmarking against a peer group helps the compensation committee determine the competitiveness of its pay plans as well as demonstrate the alignment of pay and performance relative to peers. When selecting a peer group, committees typically consider industry, size and other qualitative factors such as competition for talent, global footprint or unique situational factors that may drive the selection of particular companies (e.g., a significant change in business strategy or major market shift). The Center believes companies should clearly explain the rationale for selecting a peer group. Proxy advisors such as ISS and Glass Lewis determine their own peer groups in conducting their pay for performance assessments which significantly influence their say on pay vote recommendations. The peer group selection methods used by ISS and Glass Lewis differ in their approach – ISS relies on the GICS industry classifications of the target company and its selected peers, whereas Glass Lewis uses peers generated by Equilar through its market-based “peer of peers” methodology. The Center’s view is that neither solution is a substitute for the reasoned judgment of the compensation committee, who is in a unique position to properly determine the companies against whom the company competes for market share and talent.
Trial results?? According to gov Clinical Trials site. They have not even started a trial. Its just hard to understand why Dalio would put up with this dysfunctional #$%$. VASO doesn't run trial, but it is reasonable to assume they know what IS going on, and they refuse to comment. That is very much is line with this secrecy that permeates this organization. They really should be a private company with the obvious distain they hold for us shareholders)THE owners of this friggin company.
Where is GE extension? Where is the acquisition? Where is the buyback? Where is the OEM agreement? Where are the additional GE products? Where is PMA update? How about the CED?
The management teams proves everyday why they are not worth the salary and bonuses and stock grants we pay them.................600k to Chairman Ma? Give me a break.
I expect numbers to be released on time, and CC to be handled in a more professional manner.
The tone here is the exact opposite than last Q going into the numbers. Stock has settled about 40% off the highs and is doing what vaso's stock does; its basing. No run up into earnings is a very good thing.
In all my years of following this stock, I have never seen so much pessimism. I think its very much overdone. Wall st is a contrary place, so maybe this is a very good thing.
My motivation for taking up our little group was to inspire change at the top. This doesn't happen overnight. Vaso's EECP device remains the same lifesaving instrument it did when we all first bought into this company. Some things just need a little "push" to get them where they should be. Can our group be that catalyst?
I am betting Ma is a reasonable man and wants what we want, and I have no desire to sell. Time will tell.
See some of you at the meeting.............bob
12 million cash. Still a very big number for a BB with this market cap.
Big news; PMA on EECP for CHF has been submitted to FDA. That is money well spent.
Forecast lower expenses due to PSK.
Seems swayable on increase buyback.
Will address at shareholder meeting..............................................
Mystocks. You are free to post any positive facts about management that you like, but considering the extent of your DD postings have been to advertise your intended alleged buys, I don't think you have much to offer in that regard.
And I have no intention of selling. My comments are all fact based and meant to alert the Board and Ma that business as usual is not acceptable. Short term, shareholders demands remain; add to buyback and a message from management that they are targeting SG&A.
These are the words of Ray Dalio,(Wall St Journal today) head of the largest hedge fund in the world. His connection to vaso is that he financed a new heart center at Stony Brook to study effects of EECP. A year into this 2 year initiative, no studies have even started. When Ma commented on this, he said he didn't know why and if shareholders wanted to know "they should call themselves to find out."
Dalio says all businesses, economies, and even people, are just machines. And its very clear, he would classify the corporate Vasomedical as a broken machine. "A firm should encourage everyone to accept unvarnished criticism as a treasured opportunity to learn and solve problems." But as shareholder meeting, vaso's BOD and Ma dismissed critics by saying they didn't know what they were talking about(we are just traders) or deflecting by congratulating themselves on saving company over 4 years ago with GEHC. BOD and Ma always respond with the "lower level you", and therefore nothing is learned and no positive change can occur; no truth and certainly no transparency at Vaso.....................................................
Long term shareholders deserve better.
At this rate, we will be at a dime by the shareholder meeting. There has been no stock done on offer since CC. Ma needs to own this decline. We don't need a CEO who blames market conditions and a dilutive transaction that took place 3 years ago. Ma raised expectation for Q and then missed #'s and then gave a horrible CC. Those are the undeniable facts.
Shareholder Meeting? Reality Check for Dr Ma
WESTBURY, N.Y., June 12, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO) announced today that Stony Brook Medicine's new Center for Cardiovascular Wellness and Preventive Research will feature the Company's EECP Therapy devices in the treatment of vascular endothelial dysfunction and in preventing the onset and progression of cerebral, coronary and peripheral vascular diseases.
According to Stony Brook Medicine's public announcement, the center was made possible as a result of several recent philanthropic gifts that were matched dollar for dollar by the Simons Foundation Challenge Grant, doubling their impact and totaling in excess of $7.5 million. The center will conduct groundbreaking research into cardiovascular health and to identify and develop new options for the treatment and prevention of coronary artery disease, heart failure and Alzheimer's disease. It will focus on EECP Therapy, an FDA-cleared, non-invasive therapeutic device manufactured by Vasomedical that reduces the workload of the heart and increases blood flow to the coronary arteries and other organs of the body.
Dr. Michael Poon, a professor of Emergency Medicine, Medicine (Cardiology), and Radiology, and Director of Advanced Cardiovascular Imaging at Stony Brook Medicine, is leading the research efforts at the new center. Research at the center could ultimately benefit not only patients with or at risk of developing coronary artery disease, but also heart failure and Alzheimer's disease, which are disorders that could be caused by vascular endothelial dysfunction, as the results are translated into new approaches to patient care and disease prevention. Additional exploratory research will examine the use of EECP Therapy in preventing muscle soreness and injury in elite athletes.
"At Vasomedical, we have been proponents of EECP Therapy for almost 20 years, seeing incredible benefits to many different patient populations. Stony Brook University was among the first in the United States
This guy was at the shareholder meeting. He didn't say a word as shareholders voiced their many complaints. There were zero positive comments. He must be senile to put up with this management team and their strategy. He is 95, and company is talking about long, long term plans and diversifying away from the reason he is in this company; EECP. And stock is falling since meeting
He is the major shareholder and could dictate a more shareholder friendly agenda. How is he and his brother or their heirs ever going to monetize their 100 million shares. Its incredible.
It looks to me that ma and company know he is not all there and are taking advantage of his advanced age.
You know he would tear Ma and BOD a new one if he was in his prime. He didn't get to his position in life by enabling such incompetence..............................
Courage? You think you need courage to post on an anonymous forum? You need to change that name from Major to minor.
Do a little DD on you own, skippy.
Vaso had no problem having someone at the company comment on the Stony Brook trial when it was first announced. But now, after a year, they will not give any news or update on progress or lack of progress. They say they don't want to bias an independent trial. This is pure Ma-speak and is just another excuse for lack of transparency here.
There is ZERO doubt that vaso knows what the problem is here, yet they refuse to share anything with shareholders. You know Ma must talk with Poon.
These trials were a big reason many long termers stayed with vaso and indeed added to shares. Now, just like India or CMS upgrade............................nothing. Is this why we pay Ma 600 grand and 100 grand in expenses????? Is this the value added that one would expect a highly paid CEO to bring? Is this what our compensation committee, lead by big mouth, overpaid Castle, sees when he says Ma is actually UNDERPAID by 100k. Its all one big, indefensible disgrace.
300+ mil market cap. They are an ocular company that focuses on inherited retinal diseases. No products, no P3, no P2, just a couple P1. They just got bought out. Cross border? Maybe, but still little rgrx gets no respect.
What we wouldn't do for some new leadership
Just bizarre trading here. Yesterday almost 400k traded; up 5 cents; almost 20%. Today down 5 cents on less that 8 thousand shares. This dysfunctional trading is emblematic of our non performing BOD and CEO.
And shop still closed. Is this anyway to run a company???????? Wake up Ma, Leiberman, and Castle; our 3 stooges.
I guess this falls into the "if you cant beat'em, join'em. And since VASO doesn't feel the need to file an 8K, we, the shareholders, have really no clue as to what the details of this arrangement are.
You think maybe Coke would let Pepsi sell their product? Just think of the cost savings. I don't know where Ma gets his business acumen. ??!?!??!??!!?!?
The incompetence of Ma does make one a little angry: so many years and high opportunity costs. And shareholders like yourself who don't seem to engage management, just enable them. Just sit back and watch shares decline.
My point of your complacency with just holding cash internally as you suggest is that that provides no cushion for shareholders. And given Ma's skills, it wont be long before stock IS trading at cash value. But that's ok with you.
I don't know any real shareholder who doesn't prefer a stable price around 29 cents for the next couple months (something buyback would provide) while plan takes effect vs a steady decline to the teens. I cant see logic of your argument if you really own shares. Keep cash for a rainy day. Give me a break.
Do you even have a clue where stock price would be without the last buyback?? Oh, I forgot, you don't care about stock price as long as vaso keeps its rainy day fund; for company parties and unearned bonuses.
Did you attend the sales party?
"EECp is a huge success". For who? Certainly not for shareholders so far. Dr ma has certainly benefited greatly from vaso; 2012 compensation was almost 600,000 dollars.
PJ, do you and your buddy fritz think that is a fair sum? Or maybe you think he is underpaid.
Hope to see you both at the shareholder meeting.